News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Drugs & Diseases

      propantheline (Rx)

      Brand and Other Names:Pro Banthine
      • Print

      Dosing & Uses

      AdultPediatricGeriatric

      Dosage Forms & Strengths

      tablet

      • 15mg

      Peptic Ulcer

      15 mg PO q8hr AC & 30 mg PO qHS

      Use 7.5 mg PO q8hr for mild conditions

      Administration: take 30-60 min before a meal

      Antispasmodic

      15 mg PO q8hr AC & 30 mg PO qHS

      Other Indications & Uses

      PUD (adjunctive treatment)

      Off-label: Other conditions requiring antispasmodic and antisecretory agents, neurogenic bladder

      Dosage Forms & Strengths

      tablet

      • 15mg

      Antisecretory

      1-2 mg/kg/day PO q6-8hr  

      Antispasmodic

      2-3 mg/kg/day PO divided q4-6hr & qHS  

      Peptic Ulcer

      Safety & efficacy not established

      Administration

      Take 30-60 min before a meal

      Avoid except in short-term situations to decrease secretions; high incidence of anticholinergic effects (Beers Criteria)

      Peptic Ulcer

      Administer 7.5 mg PO q8hr AC and qHS; not to exceed 30 mg q8hr

      Antispasmodic

      15 mg PO q8hr AC & 30 mg PO qHS

      Next:

      Interactions

      Interaction Checker

      and propantheline

      No Results

         activity indicator 
        No Interactions Found
        Interactions Found

        Contraindicated

          Serious - Use Alternative

            Significant - Monitor Closely

              Minor

                All Interactions Sort By:
                 activity indicator 

                Contraindicated (0)

                  Serious - Use Alternative (7)

                  • glucagon

                    glucagon increases toxicity of propantheline by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .

                  • glucagon intranasal

                    glucagon intranasal increases toxicity of propantheline by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .

                  • glycopyrronium tosylate topical

                    glycopyrronium tosylate topical, propantheline. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.

                  • pramlintide

                    pramlintide, propantheline. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.

                  • revefenacin

                    revefenacin and propantheline both decrease cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects.

                  • secretin

                    propantheline decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.

                  • umeclidinium bromide/vilanterol inhaled

                    propantheline, umeclidinium bromide/vilanterol inhaled. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Concomitant use with other anticholinergic-containing drugs may lead to additive anticholinergic adverse effects.

                  Monitor Closely (99)

                  • abobotulinumtoxinA

                    abobotulinumtoxinA increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .

                  • aclidinium

                    propantheline and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • amantadine

                    propantheline, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.

                  • amitriptyline

                    propantheline and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • amoxapine

                    propantheline and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • anticholinergic/sedative combos

                    anticholinergic/sedative combos and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • aripiprazole

                    propantheline decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.

                    aripiprazole increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • atracurium

                    atracurium and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • atropine

                    atropine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • atropine IV/IM

                    atropine IV/IM and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • belladonna alkaloids

                    belladonna alkaloids and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • belladonna and opium

                    belladonna and opium and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • benperidol

                    propantheline decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.

                    benperidol increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • benztropine

                    benztropine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use.

                  • bethanechol

                    bethanechol increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • buprenorphine, long-acting injection

                    buprenorphine, long-acting injection increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of buprenorphine with anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.

                  • carbachol

                    carbachol increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • cevimeline

                    cevimeline increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • chlorpromazine

                    propantheline decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    chlorpromazine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • cisatracurium

                    cisatracurium and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • clomipramine

                    propantheline and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • clozapine

                    propantheline decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.

                    clozapine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • cyclizine

                    cyclizine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • cyclobenzaprine

                    cyclobenzaprine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • darifenacin

                    darifenacin and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • desipramine

                    propantheline and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • dicyclomine

                    dicyclomine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • digoxin

                    propantheline will increase the level or effect of digoxin by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Measure serum digoxin concentrations before initiating concomitant drugs; reduce digoxin dose by approximately 15% to 30% or by modifying dosing frequency and continue monitoring

                  • diphenhydramine

                    diphenhydramine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • donepezil

                    donepezil increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • donepezil transdermal

                    donepezil transdermal, propantheline. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.

                  • dosulepin

                    propantheline and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • doxepin

                    propantheline and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • droperidol

                    propantheline decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

                    droperidol increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • echothiophate iodide

                    echothiophate iodide increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • fesoterodine

                    fesoterodine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • flavoxate

                    flavoxate and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • fluphenazine

                    propantheline decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    fluphenazine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • galantamine

                    galantamine increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • glycopyrrolate

                    glycopyrrolate and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • glycopyrrolate inhaled

                    glycopyrrolate inhaled and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • haloperidol

                    propantheline decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.

                    haloperidol increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • henbane

                    henbane and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • homatropine

                    homatropine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • huperzine A

                    huperzine A increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • hyoscyamine

                    hyoscyamine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • hyoscyamine spray

                    hyoscyamine spray and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • iloperidone

                    propantheline decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.

                    iloperidone increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • imipramine

                    propantheline and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • ipratropium

                    ipratropium and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.

                  • levodopa

                    propantheline, levodopa. Other (see comment). Use Caution/Monitor. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .

                  • lofepramine

                    propantheline and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • loxapine

                    propantheline decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.

                    loxapine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • loxapine inhaled

                    loxapine inhaled increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                    propantheline decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.

                  • maprotiline

                    propantheline and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • meclizine

                    meclizine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • methscopolamine

                    methscopolamine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • metoclopramide intranasal

                    propantheline will decrease the level or effect of metoclopramide intranasal by Other (see comment). Use Caution/Monitor. Coadministration of metoclopramide intranasal with drugs that impair GI motility may decrease systemic absorption of metoclopramide. Monitor for reduced therapeutic effect.

                  • neostigmine

                    neostigmine increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • nortriptyline

                    propantheline and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • olanzapine

                    propantheline decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.

                    olanzapine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • oliceridine

                    propantheline increases toxicity of oliceridine by Other (see comment). Use Caution/Monitor. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.

                  • onabotulinumtoxinA

                    onabotulinumtoxinA and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • orphenadrine

                    propantheline and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • oxybutynin

                    oxybutynin and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • oxybutynin topical

                    oxybutynin topical and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • oxybutynin transdermal

                    oxybutynin transdermal and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • paliperidone

                    propantheline decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor.

                    paliperidone increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • pancuronium

                    pancuronium and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • perphenazine

                    propantheline decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    perphenazine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • physostigmine

                    physostigmine increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • pilocarpine

                    pilocarpine increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • pimozide

                    propantheline decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.

                    pimozide increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • prabotulinumtoxinA

                    propantheline, prabotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.

                  • pralidoxime

                    pralidoxime and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • prochlorperazine

                    propantheline decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    prochlorperazine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • promethazine

                    propantheline decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    promethazine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • protriptyline

                    propantheline and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • pyridostigmine

                    pyridostigmine increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • quetiapine

                    propantheline decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor.

                    quetiapine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • rapacuronium

                    propantheline and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • risperidone

                    propantheline decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.

                    risperidone increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • rocuronium

                    propantheline and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • scopolamine

                    propantheline and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • solifenacin

                    propantheline and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • succinylcholine

                    succinylcholine increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • thioridazine

                    propantheline decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    thioridazine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • thiothixene

                    propantheline decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.

                    thiothixene increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • tiotropium

                    propantheline and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • tolterodine

                    propantheline and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • trazodone

                    propantheline and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • trifluoperazine

                    propantheline decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    trifluoperazine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • trihexyphenidyl

                    propantheline and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.

                  • trimipramine

                    propantheline and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • trospium chloride

                    propantheline and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • umeclidinium bromide

                    umeclidinium bromide and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor. If possible, avoid coadministration of additional anticholinergic agents

                  • vecuronium

                    propantheline and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • ziprasidone

                    propantheline decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.

                    ziprasidone increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • zotepine

                    propantheline decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    propantheline decreases levels of zotepine by pharmacodynamic antagonism. Use Caution/Monitor.

                  Minor (3)

                  • dimenhydrinate

                    dimenhydrinate increases toxicity of propantheline by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

                  • donepezil

                    donepezil decreases effects of propantheline by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • galantamine

                    galantamine decreases effects of propantheline by pharmacodynamic antagonism. Minor/Significance Unknown.

                  Previous
                  Next:

                  Adverse Effects

                  >10%

                  Constipation

                  Dry mouth

                  Dry skin

                  Decreased sweating

                  Frequency Not Defined

                  Blurred vision

                  Sedation

                  Tachycardia

                  Dysphagia

                  Urinary retention

                  Previous
                  Next:

                  Warnings

                  Contraindications

                  Hypersensitivity to propantheline or related compounds

                  Closed-angle glaucoma, myasthenia gravis, hemorrhage w/ cardiovascular instability, paralytic ileus, intestinal atony of elderly/debilitated pt, obstructive uropathy, toxic megacolon, GI obstruction, tachycardia secondary to cardiac insufficiency or thyrotoxicosis

                  Cautions

                  Renal/hepatic/ impairment, BPH, CHF, CAD, HTN, COPD, hiatal hernia, reflux esophagitis, mitral stenosis, brain damage or spastic paralysis in children, salivary secretion d/o, Down synd, autonomic neuropathy, hyperthyroidism, tachyarrythmia, toxin-mediated diarrhea

                  Elderly (see Beers Criteria)

                  Risk of heat prostration in high environmental temperature

                  May affect alertness/ability to perform hazardous tasks

                  Previous
                  Next:

                  Pregnancy & Lactation

                  Pregnancy Category: C

                  Lactation: not known whether excreted into breast milk

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Mechanism of Action

                  Competitively blocks the action of ACh at postganglionic parasympathetic muscarinic receptor sites

                  Absorption

                  Bioavailability: PO <50%, take 30 min before meals

                  Onset: 30-45 min (PO)

                  Duration: Upt to 6 hr (PO)

                  Metabolism

                  Liver and GI tract

                  Elimination

                  Half-life elimination: Biphasic: 57.9 min and 2.93 hr

                  Total Body Clearance: 79.2 L/hr

                  Renal Clearance: 11.5 L/hr

                  Excretion: Urine 6-17.3%, bile, and other body fluid

                  Previous
                  Next:

                  Images

                  No images available for this drug.
                  Previous
                  Next:

                  Patient Handout

                  A Patient Handout is not currently available for this monograph.
                  Previous
                  Next:

                  Formulary

                  FormularyPatient Discounts

                  Adding plans allows you to compare formulary status to other drugs in the same class.

                  To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                  Create Your List of Plans

                  Adding plans allows you to:

                  • View the formulary and any restrictions for each plan.
                  • Manage and view all your plans together – even plans in different states.
                  • Compare formulary status to other drugs in the same class.
                  • Access your plan list on any device – mobile or desktop.

                  The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                  View explanations for tiers and restrictions
                  Tier Description
                  1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                  2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                  3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                  4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  NC NOT COVERED – Drugs that are not covered by the plan.
                  Code Definition
                  PA Prior Authorization
                  Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                  QL Quantity Limits
                  Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                  ST Step Therapy
                  Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                  OR Other Restrictions
                  Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                  CLOSE
                  Additional Offers
                  CLOSE
                  Email to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  CLOSE
                  Email Forms to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
                  Find Us On
                  About
                  About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
                  Membership
                  Become a Member About You Professional Information Newsletters & Alerts Market Research
                  App
                  Medscape
                  WebMD Network
                  Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
                  Editions
                  English Deutsch Español Français Português UK
                  All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.